Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

J&J Braces For Q1 Earnings With Bearish Charts And Patent Cliffs In Play

Published 15/04/2024, 21:47
© Reuters.  J&J Braces For Q1 Earnings With Bearish Charts And Patent Cliffs In Play

Benzinga - by Surbhi Jain, .

Johnson & Johnson (NYSE:JNJ), will be reporting its first-quarter earnings on April 16. Wall Street expects $2.64 in EPS and $21.4 billion in revenues as the company reports before market hours.

Johnson & Johnson stock is down about 9.54% over the past year, and has dropped 5.88% YTD.

The company confronts patent cliffs that threaten tens of billions in revenue, yet it’s strengthening its cardiac business by acquiring Shockwave Medical for $12.5 billion.

Johnson & Johnson's Stelara is facing increased competition from biosimilars, yet the company is offsetting these challenges with market share gains from newer drugs like Carvykti and Spravato. Meanwhile, strategic acquisitions of Abiomed and Laminar are anticipated to bolster its MedTech segment, countering near-term headwinds.

Let’s take a look at how the stock is technically setup, as it heads into Q1 earnings.

Also Read: Benzinga’s ‘Stock Whisper’ Index: 5 Stocks Investors Secretly Monitor But Don’t Talk About Yet

J&J Stock Technical Setup Ahead Of Q1 Earnings

Chart: Benzinga Pro

The share price is below its 5, 20, and 50-day exponential moving averages, reinforcing the bearish sentiment. Additionally, the stock’s price has fallen below its 200-day simple moving average, further signaling a bear trend.

Chart: Benzinga Pro

The Moving Average Convergence Divergence (MACD) at -2.59 indicator supports a bearish sentiment, although the Relative Strength Index (RSI) at 26.32 suggests J&J stock is deeply oversold.

For over a month now, J&J stock has been trading in the lower of the Bollinger Bands, indicating bearish sentiments for both short-term and long-term trends. Investors may want to exercise caution and monitor JNJ’s performance closely amid the current technical setup.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

J&J Analysts Consensus Ratings

Ratings & Consensus Estimates:

According to the latest analyst ratings from Cantor Fitzgerald and RBC Capital, Johnson & Johnson’s stock has an average price target of $203.67, indicating a potential 37.15% upside from current levels.

Price Action: Shares of Johnson & Johnson were up 0.04% to $147.59 on Monday.

Read Next: A Closer Look at 9 Analyst Recommendations For Johnson & Johnson

Photo: Shutterstock

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.